{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T02:06:57Z","timestamp":1792980417968,"version":"4.5.0"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>There are known risks of using opioids for extended periods. However, less is known about the long-term trajectories of opioid use following initiation.<\/jats:p><\/jats:sec>Objective<\/jats:title>To identify 5-year trajectories of prescription opioid use, and to examine the characteristics of each trajectory group.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This population-based cohort study conducted in New South Wales, Australia, linked national pharmaceutical claims data to 10 national and state data sets to determine sociodemographic characteristics, clinical characteristics, drug use, and health services use. The cohort included adult residents (aged \u226518 years) of New South Wales who initiated a prescription opioid between July 1, 2003, and December 31, 2018. Statistical analyses were conducted from February to September 2022.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Dispensing of a prescription opioid, with no evidence of opioid dispensing in the preceding 365 days, identified from pharmaceutical claims data.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The main outcome was the trajectories of monthly opioid use over 60 months from opioid initiation. Group-based trajectory modeling was used to classify these trajectories. Linked health care data sets were used to examine characteristics of individuals in different trajectory groups.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 3\u202f474\u202f490 individuals who initiated a prescription opioid (1\u202f831\u202f230 females [52.7%]; mean [SD] age, 49.7 [19.3] years), 5 trajectories of long-term opioid use were identified: very low use (75.4%), low use (16.6%), moderate decreasing to low use (2.6%), low increasing to moderate use (2.6%), and sustained use (2.8%). Compared with individuals in the very low use trajectory group, those in the sustained use trajectory group were older (age \u226565 years: 22.0% vs 58.4%); had more comorbidities, including cancer (4.1% vs 22.2%); had increased health services contact, including hospital admissions (36.9% vs 51.6%); had higher use of psychotropic (16.4% vs 42.4%) and other analgesic drugs (22.9% vs 47.3%) prior to opioid initiation, and were initiated on stronger opioids (20.0% vs 50.2%).<\/jats:p><\/jats:sec>Conclusions and relevance<\/jats:title>Results of this cohort study suggest that most individuals commencing treatment with prescription opioids had relatively low and time-limited exposure to opioids over a 5-year period. The small proportion of individuals with sustained or increasing use was older with more comorbidities and use of psychotropic and other analgesic drugs, likely reflecting a higher prevalence of pain and treatment needs in these individuals.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.28159","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T15:04:10Z","timestamp":1691679850000},"page":"e2328159","source":"Crossref","is-referenced-by-count":19,"title":["Five-Year Trajectories of Prescription Opioid Use"],"prefix":"10.1001","volume":"6","author":[{"given":"Natasa","family":"Gisev","sequence":"first","affiliation":[{"name":"National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Buizen","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ria E.","family":"Hopkins","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Schaffer","sequence":"additional","affiliation":[{"name":"School of Population Health, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia"},{"name":"Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Daniels","sequence":"additional","affiliation":[{"name":"School of Population Health, UNSW Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrianna","family":"Bharat","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Dobbins","sequence":"additional","affiliation":[{"name":"School of Population Health, UNSW Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Larney","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Emergency Medicine and Centre de Recherche du Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Blyth","sequence":"additional","affiliation":[{"name":"School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Currow","sequence":"additional","affiliation":[{"name":"Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wilson","sequence":"additional","affiliation":[{"name":"Menzies Centre for Health Policy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sallie-Anne","family":"Pearson","sequence":"additional","affiliation":[{"name":"School of Population Health, UNSW Sydney, Sydney, New South Wales, Australia"},{"name":"Menzies Centre for Health Policy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Degenhardt","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"issue":"10028","key":"zoi230811r1","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/S0140-6736(16)00161-6","article-title":"Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study.","volume":"387","author":"Berterame","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"zoi230811r2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/bcp.v85.1","article-title":"Prevalence and incidence of prescription opioid analgesic use in Australia.","volume":"85","author":"Lalic","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"22","key":"zoi230811r3","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1001\/jama.2016.7789","article-title":"Prescription of long-acting opioids and mortality in patients with chronic noncancer pain.","volume":"315","author":"Ray","year":"2016","journal-title":"JAMA"},{"key":"zoi230811r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101558","article-title":"Long-term opioid use and mortality in patients with chronic non-cancer pain: ten-year follow-up study in South Korea from 2010 through 2019.","volume":"51","author":"Song","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"4","key":"zoi230811r5","doi-asserted-by":"publisher","first-page":"276","DOI":"10.7326\/M14-2559","article-title":"The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop.","volume":"162","author":"Chou","year":"2015","journal-title":"Ann Intern Med"},{"issue":"10","key":"zoi230811r6","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1111\/bcp.v87.10","article-title":"Variations in long-term opioid therapy definitions: a systematic review of observational studies using routinely collected data (2000-2019).","volume":"87","author":"de Oliveira Costa","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"zoi230811r7","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1097\/ALN.0000000000003265","article-title":"Persistent postoperative opioid use: a systematic literature search of definitions and population-based cohort study.","volume":"132","author":"Jivraj","year":"2020","journal-title":"Anesthesiology"},{"issue":"3","key":"zoi230811r8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/ejp.2012.16.issue-3","article-title":"Differential patterns of opioid use: defining persistent opioid use in a prescription database.","volume":"16","author":"Svendsen","year":"2012","journal-title":"Eur J Pain"},{"issue":"6","key":"zoi230811r9","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/bcp.13556","article-title":"Predictors of persistent prescription opioid analgesic use among people without cancer in Australia.","volume":"84","author":"Lalic","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"zoi230811r10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222677","article-title":"Trajectories of prescription opioids filled over time.","volume":"14","author":"Elmer","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"zoi230811r11","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1080\/02791072.2020.1856456","article-title":"Prevalence and its correlation with sustained opioid use in Korea: a group-based trajectory analysis.","volume":"53","author":"Yoon","year":"2021","journal-title":"J Psychoactive Drugs"},{"issue":"1","key":"zoi230811r12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210341","article-title":"Patterns and predictors of chronic opioid use in older adults: a retrospective cohort study.","volume":"14","author":"Oh","year":"2019","journal-title":"PLoS One"},{"issue":"12","key":"zoi230811r13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025840","article-title":"Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol.","volume":"8","author":"Gisev","year":"2018","journal-title":"BMJ Open"},{"issue":"5","key":"zoi230811r14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-068310","article-title":"Cohort profile: POPPY II\u2014a population-based cohort examining the patterns and outcomes of prescription opioid use in New South Wales, Australia.","volume":"13","author":"Gisev","year":"2023","journal-title":"BMJ Open"},{"key":"zoi230811r15","doi-asserted-by":"publisher","first-page":"k3532","DOI":"10.1136\/bmj.k3532","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE).","volume":"363","author":"Langan","year":"2018","journal-title":"BMJ"},{"key":"zoi230811r17","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1186\/s13104-015-1616-8","article-title":"The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers.","volume":"8","author":"Mellish","year":"2015","journal-title":"BMC Res Notes"},{"issue":"5","key":"zoi230811r19","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/pds.v27.5","article-title":"To what extent do data from pharmaceutical claims under-estimate opioid analgesic utilisation in Australia?","volume":"27","author":"Gisev","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"zoi230811r23","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/pds.3945","article-title":"A synthesis of oral morphine equivalents (OME) for opioid utilisation studies.","volume":"25","author":"Nielsen","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"zoi230811r26","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.2147\/CLEP.S265287","article-title":"Trajectory modelling techniques useful to epidemiological research: a comparative narrative review of approaches.","volume":"12","author":"Nguena Nguefack","year":"2020","journal-title":"Clin Epidemiol"},{"key":"zoi230811r27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1146\/clinpsy.2010.6.issue-1","article-title":"Group-based trajectory modeling in clinical research.","volume":"6","author":"Nagin","year":"2010","journal-title":"Annu Rev Clin Psychol"},{"issue":"3","key":"zoi230811r28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/pds.v29.3","article-title":"Opening the black box of the group-based trajectory modeling process to analyze medication adherence patterns: an example using real-world statin adherence data.","volume":"29","author":"Hickson","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"zoi230811r29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/wics.v4.2","article-title":"The bayesian information criterion: background, derivation, and applications.","volume":"4","author":"Neath","year":"2012","journal-title":"WIREs Computational Statistics"},{"issue":"3","key":"zoi230811r30","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.sapharm.2012.04.004","article-title":"Interrater agreement and interrater reliability: key concepts, approaches, and applications.","volume":"9","author":"Gisev","year":"2013","journal-title":"Res Social Adm Pharm"},{"issue":"2","key":"zoi230811r31","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/ejp.v24.2","article-title":"Efficacy and harms of long-term opioid therapy in chronic non-cancer pain: systematic review and meta-analysis of open-label extension trials with a study duration =26 weeks.","volume":"24","author":"Bialas","year":"2020","journal-title":"Eur J Pain"},{"issue":"6","key":"zoi230811r32","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/add.v115.6","article-title":"Transition to high-dose or strong opioids: a population-based study of people initiating opioids in Australia.","volume":"115","author":"Lalic","year":"2020","journal-title":"Addiction"},{"issue":"10","key":"zoi230811r33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003270","article-title":"Time trends and prescribing patterns of opioid drugs in UK primary care patients with non-cancer pain: a retrospective cohort study.","volume":"17","author":"Jani","year":"2020","journal-title":"PLoS Med"},{"issue":"2","key":"zoi230811r34","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/01.j.pain.0000460303.63948.8e","article-title":"The Pain and Opioids IN Treatment study: characteristics of a cohort using opioids to manage chronic non-cancer pain.","volume":"156","author":"Campbell","year":"2015","journal-title":"Pain"},{"issue":"1","key":"zoi230811r35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11606-016-3810-3","article-title":"Association between initial opioid prescribing patterns and subsequent long-term use among opioid-na\u00efve patients: a statewide retrospective cohort study.","volume":"32","author":"Deyo","year":"2017","journal-title":"J Gen Intern Med"},{"issue":"4","key":"zoi230811r36","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/bcp.13026","article-title":"Initiation of strong prescription opioids in Australia: cohort characteristics and factors associated with the type of opioid initiated.","volume":"82","author":"Gisev","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"zoi230811r37","first-page":"e97","article-title":"Chronic noncancer pain: characteristics of patients prescribed opioids by community physicians and referred to a tertiary pain clinic.","volume":"57","author":"Mailis-Gagnon","year":"2011","journal-title":"Can Fam Physician"},{"issue":"16","key":"zoi230811r38","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1200\/JCO.2013.52.5188","article-title":"Principles of opioid use in cancer pain.","volume":"32","author":"Portenoy","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi230811r39","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","article-title":"Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC.","volume":"13","author":"Caraceni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi230811r40","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/j.pain.0000000000000730","article-title":"Incident and long-term opioid therapy among patients with psychiatric conditions and medications: a national study of commercial health care claims.","volume":"158","author":"Quinn","year":"2017","journal-title":"Pain"},{"issue":"12","key":"zoi230811r41","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1093\/pm\/pnz009","article-title":"Antidepressant use among people prescribed opioids for chronic noncancer pain.","volume":"20","author":"Gisev","year":"2019","journal-title":"Pain Med"},{"issue":"3","key":"zoi230811r42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003947","article-title":"Trajectories of prescription opioid dose and risk of opioid-related adverse events among older Medicare beneficiaries in the United States: a nested case-control study.","volume":"19","author":"Wei","year":"2022","journal-title":"PLoS Med"},{"issue":"12","key":"zoi230811r43","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1007\/s10461-019-02608-3","article-title":"Patterns and correlates of prescription opioid receipt among US veterans: a national, 18-year observational cohort study.","volume":"23","author":"Rentsch","year":"2019","journal-title":"AIDS Behav"},{"issue":"10","key":"zoi230811r44","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/pds.v31.10","article-title":"Association between opioid therapy trajectories and potential opioid-related adverse health events.","volume":"31","author":"Hayes","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"zoi230811r16","unstructured":"Australian Bureau of Statistics. 3101.0\u2014Australian demographic statistics, Jun 2018. Accessed March 4, 2022. https:\/\/www.abs.gov.au\/AUSSTATS\/abs@.nsf\/Lookup\/3101.0Main+Features1Jun%202018?OpenDocument=?"},{"key":"zoi230811r18","unstructured":"Australian Government Department of Health and Aged Care. The Pharmaceutical Benefits Scheme: about the PBS. Accessed July 29, 2022. https:\/\/www.pbs.gov.au\/info\/about-the-pbs?"},{"key":"zoi230811r20","unstructured":"Australian Bureau of Statistics. 1270.0.55.005\u2014Australian Statistical Geography Standard (ASGS): volume 5\u2014remoteness structure, July 2016. Accessed January 29, 2021. https:\/\/www.abs.gov.au\/AUSSTATS\/abs@.nsf\/Lookup\/1270.0.55.005Main+Features1July%202016?OpenDocument"},{"key":"zoi230811r21","unstructured":"Australian Bureau of Statistics. 1216.0.15.003\u2014Australian Standard Geographical Classification (ASGC) remoteness area correspondences, 2006. Accessed August 31, 2020. http:\/\/www.abs.gov.au\/AUSSTATS\/abs@.nsf\/Lookup\/1216.0.15.003Main+Features12006?OpenDocument?"},{"key":"zoi230811r22","unstructured":"Pink? B. Socio-Economic Indexes for Areas (SEIFA) 2011: Technical Paper\u2014Australian Bureau of Statistics Commonwealth of Australia; 2013. Accessed September 22, 2020. https:\/\/www.ausstats.abs.gov.au\/ausstats\/subscriber.nsf\/0\/22CEDA8038AF7A0DCA257B3B00116E34\/$File\/2033.0.55.001%20seifa%202011%20technical%20paper.pdf"},{"key":"zoi230811r24","unstructured":"World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision. 2015. Accessed August 4, 2020. https:\/\/apps.who.int\/classifications\/icd10\/browse\/2015\/en"},{"key":"zoi230811r25","unstructured":"World Health Organization Collaborating Centre for Drugs Statistics Methodology. ATC\/DDD index 2021. Accessed March 4, 2021. https:\/\/www.whocc.no\/atc_ddd_index\/?"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2808144\/gisev_2023_oi_230811_1690904150.22973.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T15:04:17Z","timestamp":1691679857000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2808144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.28159","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]}}}